GastroAGI Logo
OverviewBlogsAbout
Trending TopicsDaily BriefConference

Trending Topics in Gastroenterology

Explore current gastroenterology questions, clinical answers, and emerging research by topic.

161

Recurrent non-malignant ampullary neoplasms

Recurrent non-malignant ampullary neoplasms, primarily adenomas, are benign tumors located at the ampulla of Vater, a critical junction where the bile duct and pancreatic duct meet and empty...

162

FIT versus colonoscopy in Korea’s national colorectal cancer screening program

In South Korea's national colorectal cancer (CRC) screening program, the fecal immunochemical test (FIT) and colonoscopy are two key approaches, each with distinct advantages and limitations. Here's a...

163

HCC - Alcohol versus other etioloiges

Hepatocellular carcinoma (HCC), the most common type of primary liver cancer, can develop due to various etiologies. Alcohol-related liver disease (ALD) is a significant contributor to HCC, alongside...

164

Serum Tyrosine, HCC and mortality

Serum Tyrosine, Hepatocellular Carcinoma (HCC), and Mortality: Detailed Explanation What is Serum Tyrosine? Serum tyrosine is an aromatic amino acid (AAA) that plays a critical role in protein...

165

CEACAM6, HOXA-AS3 and miR-29a in colorectal cancer

CEACAM6, HOXA-AS3, and miR-29a are molecular components that play significant roles in colorectal cancer (CRC) progression, diagnosis, prognosis, and potential therapeutic strategies. Below is a detailed explanation of...

166

CD47 expression on survival of colorectal cancer

CD47 expression plays a significant role in determining the survival outcomes of colorectal cancer (CRC) patients. Here's a detailed explanation of its impact: What is CD47? CD47 is...

167

AFP-L3 or DCP expression is associated with poor outcomes in unresectable HCC

Yes, the expression of AFP-L3 or DCP is strongly associated with poor outcomes in patients with unresectable hepatocellular carcinoma (HCC), as demonstrated by the study you referenced. Here's...

168

MIER2 as a prognostic marker in colon adenocarcinoma

MIER2 as a Prognostic Marker in Colon Adenocarcinoma (COAD) What is MIER2? Mesoderm Induction Early Response 2 (MIER2) is a gene that has been identified to play a...

169

Ferroptosis and enhances immunotherapy in pancreatic cancer

Ferroptosis, an iron-dependent form of regulated cell death characterized by lipid peroxidation and oxidative damage, has emerged as a potential mechanism to overcome the resistance of pancreatic ductal...

170

MATTERHORN Trial

The MATTERHORN trial was a global, Phase 3 study that investigated the addition of Durvalumab (an immunotherapy drug) to the standard FLOT chemotherapy regimen in patients with resectable...

Previous
116171819
Next
GastroAGI Logo

We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.

For You

For StudentsFor CliniciansFor ResearchersFor Patients

Core Tools

MELD-Na ScoreChild-PughFIB-4 IndexGlasgow-BlatchfordBISAP Score

Explore

OverviewAboutCalculators
Trending Topics
Conference Briefings
Blog Insights
©GastroAGI 2026
Privacy PolicyTerms of UseMedical Disclaimer